OTCPK:PMCU.F

Stock Analysis Report

Executive Summary

Pro Medicus Limited provides radiology information systems (RIS), picture archiving and communication systems (PACS), and advanced visualization solutions in Australia, Europe, and North America.

Snowflake

Fundamentals

Exceptional growth potential with outstanding track record.


Similar Companies

Share Price & News

How has Pro Medicus's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

3.8%

PMCU.F

2.5%

US Healthcare Services

-0.6%

US Market


1 Year Return

135.5%

PMCU.F

10.2%

US Healthcare Services

0.7%

US Market

PMCU.F outperformed the Healthcare Services industry which returned 10.3% over the past year.

PMCU.F outperformed the Market in United States of America which returned 0.6% over the past year.


Share holder returns

PMCU.FIndustryMarket
7 Day3.8%2.5%-0.6%
30 Day-1.6%-1.9%2.9%
90 Day9.3%-2.9%1.3%
1 Year135.5%135.5%10.3%10.2%2.9%0.7%
3 Year342.5%342.5%51.7%51.4%44.6%35.2%
5 Year2305.2%2305.2%52.0%51.1%61.9%44.2%

Price Volatility Vs. Market

How volatile is Pro Medicus's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Pro Medicus undervalued based on future cash flows and its price relative to the stock market?

157.16x

Price to Earnings (PE) ratio


Intrinsic Value Based on Future Cash Flows

Pro Medicus's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).

Pro Medicus's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).


Price Based on Earnings

Pro Medicus is overvalued based on earnings compared to the US Healthcare Services industry average.

Pro Medicus is overvalued based on earnings compared to the United States of America market.


Price Based on Expected Growth

Pro Medicus is poor value based on expected growth next year.


Price Based on Value of Assets

Pro Medicus is overvalued based on assets compared to the US Healthcare Services industry average.


Next Steps

Future Growth

How is Pro Medicus expected to perform in the next 1 to 3 years based on estimates from 7 analysts?

27.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Pro Medicus's revenue is expected to grow significantly at over 20% yearly.

Pro Medicus's earnings are expected to grow significantly at over 20% yearly.

Pro Medicus's revenue growth is expected to exceed the United States of America market average.

Pro Medicus's earnings growth is expected to exceed the United States of America market average.

Pro Medicus's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Pro Medicus is expected to make outstanding use of shareholders’ funds in the future (Return on Equity greater than 40%).


Next Steps

Past Performance

How has Pro Medicus performed over the past 5 years?

39.3%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Pro Medicus has delivered over 20% year on year earnings growth in the past 5 years.

Pro Medicus's 1-year earnings growth exceeds its 5-year average (91.9% vs 39.3%)

Pro Medicus's earnings growth has exceeded the US Healthcare Services industry average in the past year (91.9% vs 3.3%).


Return on Equity

Pro Medicus has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).


Return on Assets

Pro Medicus used its assets more efficiently than the US Healthcare Services industry average last year based on Return on Assets.


Return on Capital Employed

Pro Medicus has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is Pro Medicus's financial position?


Financial Position Analysis

Pro Medicus is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Pro Medicus's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Pro Medicus has no debt.

Pro Medicus has not taken on any debt in the past 5 years.

Pro Medicus has no debt, it does not need to be covered by operating cash flow.

Pro Medicus has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

Low level of unsold assets.

Pro Medicus has no debt, it does not need to be covered by short term assets.


Next Steps

Dividend

What is Pro Medicus's current dividend yield, its reliability and sustainability?

0.56%

Expected Dividend Yield


Dividend Yield and Payments Analysis

Pro Medicus's pays a lower dividend yield than the bottom 25% of dividend payers in United States of America (1.44%).

Pro Medicus's dividend is below the markets top 25% of dividend payers in United States of America (3.71%).

Pro Medicus is not paying a notable dividend for United States of America, therefore no need to check if the payments are stable.

Pro Medicus is not paying a notable dividend for United States of America, therefore no need to check if the payments are increasing.


Current Payout to Shareholders

No need to calculate the sustainability of Pro Medicus's dividends as it is not paying a notable one for United States of America.


Future Payout to Shareholders

No need to calculate the sustainability of Pro Medicus's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

Management

What is the CEO of Pro Medicus's salary, the management and board of directors tenure and is there insider trading?

8.7yrs

Average management tenure


CEO

Sam Hupert 0

8.9yrs

Tenure

AU$507,916

Compensation

Dr. Sam Aaron Hupert, M.B.B.S. has been the Chief Executive Officer and Managing Director at Pro Medicus Limited (alternate name: PRO Medicus Ltd.) since October 2010. Dr. Hupert serves as Chief Executive  ...


CEO Compensation Analysis

Sam's remuneration is lower than average for companies of similar size in United States of America.

Sam's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

8.7yrs

Average Tenure

The average tenure for the Pro Medicus management team is over 5 years, this suggests they are a seasoned and experienced team.


Board Age and Tenure

9.1yrs

Average Tenure

The tenure for the Pro Medicus board of directors is about average.


Insider Trading

Pro Medicus individual insiders have only sold shares in the past 3 months.


Recent Insider Transactions

SellAU$24,765,04105 Sep 19
Sam Hupert
EntityIndividual
Role
Chief Executive Officer
Co-Founder
Shares1,000,000
Max PriceAU$24.77
SellAU$24,765,04105 Sep 19
Anthony Hall
EntityIndividual
Role
Member of the Board of Directors
Co-Founder
Shares1,000,000
Max PriceAU$24.77

Ownership Breakdown


Management Team

  • Anthony Hall

    Co-Founder

    • Tenure: 36.7yrs
    • Compensation: AU$380.27k
  • Sam Hupert

    Co-Founder

    • Tenure: 8.9yrs
    • Compensation: AU$507.92k
  • Danny Tauber

    General Manager of Australia

    • Tenure: 8.7yrs
    • Compensation: AU$560.41k
  • Malte Westerhoff

    Global Chief Technology Officer

    • Tenure: 0yrs
    • Compensation: AU$1.10m
  • Clayton Hatch

    CFO & Company Secretary

    • Tenure: 7.2yrs
  • Brad Levin

    GM of North America & Global Head of Marketing

    • Tenure: 0yrs
    • Compensation: AU$592.08k
  • Sean Lambright

    Global Head of Sales - Visage Imaging Inc

    • Tenure: 4.2yrs
    • Compensation: AU$696.30k

Board Members

  • Anthony Hall

    Co-Founder

    • Tenure: 36.7yrs
    • Compensation: AU$380.27k
  • Sam Hupert

    Co-Founder

    • Tenure: 8.9yrs
    • Compensation: AU$507.92k
  • Leigh Farrell

    Non-Executive Director

    • Tenure: 2yrs
    • Compensation: AU$90.00k
  • Peter Kempen (70yo)

    Chairman of the Board

    • Tenure: 9.1yrs
    • Compensation: AU$100.00k
  • Tony Glenning

    Non-Executive Director

    • Tenure: 3.3yrs
    • Compensation: AU$100.00k

Company Information

Pro Medicus Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Pro Medicus Limited
  • Ticker: PMCU.F
  • Exchange: OTCPK
  • Founded: 1983
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: AU$3.018b
  • Listing Market Cap: AU$2.043b
  • Shares outstanding: 103.98m
  • Website: https://www.promed.com.au

Number of Employees


Location

  • Pro Medicus Limited
  • 450 Swan Street
  • Richmond
  • Victoria
  • 3121
  • Australia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PMEASX (Australian Securities Exchange)YesOrdinary SharesAUAUDOct 2000
PMCU.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDOct 2000
PMECHIA (Chi-X Australia)YesOrdinary SharesAUAUDOct 2000
PMCDB (Deutsche Boerse AG)YesOrdinary SharesDEEUROct 2000

Biography

Pro Medicus Limited provides radiology information systems (RIS), picture archiving and communication systems (PACS), and advanced visualization solutions in Australia, Europe, and North America. It offers ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/21 23:59
End of Day Share Price2019/09/19 00:00
Earnings2019/06/30
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.